secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001193125-25-274378
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palvella Q3 net loss $11.3M; cash $63.6M; Phase 2/3 readouts on track for Dec 2025 and Q1 2026
--------------------------------------------------------------------------------

- Net loss per share $1.03 (basic/diluted) vs $3.94 a year ago; R&D expense rose to $6.5M.
- Cash & equivalents $63.6M, expected to fund operations into H2 2027.
- Phase 2 TOIVA (cutaneous VMs) top-line results expected mid-December 2025.
- Phase 3 SELVA (microcystic LMs) top-line results expected Q1 2026.
- Expanded pipeline: angiokeratomas and QTORIN pitavastatin for DSAP; Phase 2 start H2 2026; David Osborne appointed CINO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000119312525274378/0001193125-25-274378-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000119312525274378/pvla-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-274378

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer